Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S138000, C544S242000, C544S336000, C546S135000, C546S139000, C546S269400, C548S131000, C514S364000
Reexamination Certificate
active
07041685
ABSTRACT:
The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I:wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 3192103 (1965-06-01), Durden et al.
patent: 3211742 (1965-10-01), Lenaers
patent: 3325446 (1967-06-01), Chang et al.
patent: 3772441 (1973-11-01), Lombardino
patent: 3879404 (1975-04-01), Baldwin et al.
patent: 3910940 (1975-10-01), Narayanan et al.
patent: 4022901 (1977-05-01), Narayanan et al.
patent: 4791124 (1988-12-01), Lutomski et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 6121260 (2000-09-01), Thurkauf et al.
patent: 6277873 (2001-08-01), Yu et al.
patent: WO 96/20721 (1996-07-01), None
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol.162: 603-608, The American Association of Immunologists (1999).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology116:557-565, The American Gastroenterological Association (1999).
Chinnaiyan, A.M., et al., “The inhibition of the pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med.3:333-337, Nature Publishing Co. (1997).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed.15:22-27, Munksgaard (1999).
Ellis, R.E., et al., “Mechanisms and Functions of Cell Death,”Ann. Rev. Cell Biol.7:663-698, Annual Reviews, Inc. (1991).
Friesen, C., et al., “Involvement of the CD95 (APO-1/PAS) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med.2:574-577, Nature Publishing Co. (1996).
Greenwald, R.B., “Drug Deliery System Employing 1,4-or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem.42: 3657-3667, Ameircan Chemical Society (1999).
Heenen, M., et al., “Methotrexate induces apoptotic cell cell death in human keratinocytes,”Arch. Dermatol. Res.290:240-245, Springer-Verlag (1998).
Infante, A.J. et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr.133:629-633, Moaby, Inc. (1998).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT), ”J. Med. Chem.42: 623-3628, American Chemical Society (1999).
Lopez-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-Xland its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med.1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95 -and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood90:3118-3129, W. B. Saunders Co. (1997).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res.48:5-21, Birkhauser Verlag (1999).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ.6:13-21, Stockton Press (1999).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Internal Med.237:529-536, Blackwell Science Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med.189:711-718, The Rockefeller University Press (1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol.61:375-380, The Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and BAX-βcontrol points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol.75:301-314, National Research Council of Canada (1997).
Tai, D.-I., et al., “Activation of Nuclear Factor kB in Hepatitis C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis,”Hepatology3:656-664, W.B. Saunders Co. (Mar. 2000).
Thornberry, N.A., “The caspase family of cysteine proteases,”Brit. Med. Bull.53:478-490, Oxford University Press (1997).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chem. Biol.5:R97-R103, Current Biology Ltd. (1998).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations,”J. Clin. Invest.103:355-363, The American Society for Clinical Investigations (1999).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol.114:119-128, Blackwell Science (1998).
Wyllie, A.H., et al., “Cell Death: The Significance of Apoptosis,”Int. Rev. Cyt.68:251-306, Academic Press, Inc. (1980).
Wyllie, A.H., “Cell death: a new classification separating apoptosis from necrosis,” inCell death in biology and pathology, Bowen and Lockshin. eds., Chapman and Hall, London, England, pp. 9-34 (1981).
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases,”Nat. Med.5:42-48, Nature Publishing Co. (1999).
International Search Report for International Patent Application PCT/US02/17892, issued Mar. 26, 2003.
Cai Sui Xiong
Drewe John A.
Kasibhatla Shailaja
Kuemmerle Jared Daniel
Ollis Kristin P.
Cytovia, Inc.
Shameem Golam M M
Sterne, Kessler, Goldstein & Fox P.L.LC.
LandOfFree
Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3622000